Cel-Sci Corporation (CVM) vs TransCode Therapeutics Inc. (RNAZ)

Cel-Sci Corporation and TransCode Therapeutics Inc. are both Biotechnology companies. Cel-Sci Corporation and TransCode Therapeutics Inc. are of similar size ($30.3M and $27.9M). Across the 9 metrics below, TransCode Therapeutics Inc. leads on 6 and Cel-Sci Corporation on 3.

Valuation

Metric CVM RNAZ Biotechnology median
P/E n/m n/m 7.88
P/S 36.22 n/m 11.47
P/B 1.85 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.15 0.74
EV/Sales 34.83 n/m 10.73
Earnings yield (68.40%) (3,098.82%) (28.84%)
Free cash flow yield (83.02%) (1,398.93%) (23.03%)

Profitability

Metric CVM RNAZ Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (252.53%) 429.61% (57.72%)
Return on assets (108.91%) (58.12%) (49.22%)
Return on invested capital (169.59%) 0.00% 0.00%

Growth

Metric CVM RNAZ Biotechnology median
Revenue growth (TTM) 20.75% — 5.64%
EPS growth (last fiscal year) 59.06% 96.02% —
Revenue growth, 5-year CAGR 16.18% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CVM RNAZ Biotechnology median
Debt to equity 0.35 0.00 0.00
Current ratio 1.48 1.97 4.73
Net debt to EBITDA 0.25 0.64 0.96

Dividend

Metric CVM RNAZ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CVM RNAZ Biotechnology median
Market cap 30.25m 27.94m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack